Company

Professional and Personal Experience with Celiac Disease.

A team of passionate industry and research leaders dedicated to changing how celiac disease is treated.

Leadership Team

Leadership

Mark Paresky

Mark Paresky

Co-Founder and
Executive Chairman

Mark Paresky is a Co-Founder and the Executive Chairman of Interlude Biopharma and the company’s lead investor. He is President and CEO of Crimson Peak, a Miami-based investment firm. He started his career as an investment banker at J.P. Morgan and subsequently was president of an e-commerce company. He holds leadership roles at YPO and on several nonprofit boards. He has an AB in Economics from Duke University and an MBA from Northwestern’s Kellogg School of Management.

Julie Paresky

Julie Paresky

Co-Founder

Julie Paresky is a marketing and business strategy executive with experience spanning industries including Fortune 500 companies, financial services institutions, and health and wellness ventures. She began her career in Consumer Products Marketing at NBA Properties and later at Colgate-Palmolive in New York. She serves on the boards of various nonprofit organizations. Julie holds a BA from the University of Pennsylvania and an MBA from Harvard Business School.

Subbarao Jayanthi

Subbarao Jayanthi

President

Subbarao Jayanthi brings more than two decades of experience in corporate strategy, new product development and commercialization, business development and licensing, and mergers and acquisitions. He founded and led RxC, a biopharmaceutical strategy consulting firm, and previously held strategic planning responsibilities at Daiichi Sankyo and worked at Boston Consulting Group. He is a board member of Scienture (SCNX), a NASDAQ-listed company, and several private biopharma companies. Subbarao holds an MBA from Northwestern University’s Kellogg School of Management.

Jay Madan

Jay Madan

Chief Operating Officer

Jay Madan has more than three decades of experience in the life sciences industry as an operating executive, board member, and advisor. He founded and served as president of Innovate Biopharmaceuticals and led the company’s public listing. He holds a B.S. in Chemical Engineering from the University of Mumbai and an M.S. from Washington State University.

Dr. Gary Musso

Dr. Gary Musso

Chemistry, Manufacturing and Controls

Dr. Gary Musso has more than 40 years of experience in biotech and pharma, specializing in CMC regulatory strategy for peptides and small molecules. He has contributed to the development and approval of multiple drugs, including Kyprolis®, Plenaxis®, and Trulance®, and has supported the development of larazotide for approximately 15 years. He earned his Ph.D. from the University of Chicago.

Scientific Advisors

Leading celiac disease investigators and regulatory experts

Dr. Alessio Fasano

Dr. Alessio Fasano

Senior Scientific Advisor

Dr. Alessio Fasano is an internationally recognized expert in celiac disease and intestinal barrier function whose pioneering research advanced the understanding of intestinal permeability and led to the discovery of larazotide acetate. He holds the W. Allan Walker Chair of Pediatrics at Mass General Brigham and directs the Center for Celiac Research and Treatment and the Mucosal Immunology and Biology Research Center. He is Professor of Pediatrics at Harvard Medical School and Professor of Nutrition at the Harvard T.H. Chan School of Public Health. Dr. Fasano earned his M.D. and completed his pediatric residency at the University of Naples School of Medicine.

Dr. Joseph A. Murray

Dr. Joseph A. Murray

Scientific Advisor

Dr. Joseph A. Murray is the John and Shirley Berry Professor of Gastrointestinal Sciences at the Mayo Clinic, specializing in celiac disease, achalasia, and esophageal disorders. Board-certified in gastroenterology and internal medicine, he conducts NIH-funded celiac disease research and was the corresponding author of the larazotide Phase 2b publication. Dr. Murray also serves on the Beyond Celiac advisory board.

Dr. Maureen Leonard

Dr. Maureen Leonard

Scientific Advisor

Dr. Maureen Leonard, a leading researcher in celiac disease, serves as Director of the Center for Celiac Research and Treatment at Mass General for Children and is on the faculty of Harvard Medical School. She is the principal investigator of the NIH-funded CDGEMM study. She earned her M.D. from New York Medical College and a master’s in clinical and translational investigation from Harvard.

Dr. Ciaran Kelly

Dr. Ciaran Kelly

Scientific Advisor

Dr. Ciaran Kelly is the J. Thomas Lamont Professor of Gastroenterology at Beth Israel Deaconess Medical Center and a co-founder of its Celiac Center. A leader in celiac disease clinical research with more than 300 publications, he was the first author of a Phase 2 gluten-challenge study of larazotide. He is also a Professor of Medicine at Harvard Medical School and has served on FDA, NIH and CDC committees on celiac disease. He earned his medical degree from Trinity College Dublin.

Dr. Markku Mäki

Dr. Markku Mäki

Scientific Advisor

Dr. Markku Mäki is a globally recognized expert in celiac disease and former head of the Celiac Disease Study Group at Tampere University, Finland (1982–2015). With more than 500 scientific publications, he has made groundbreaking contributions to the diagnosis, pathogenesis, and treatment of celiac disease. He earned his M.D. and Ph.D. from the University of Tampere, where he also became a professor of pediatrics.

Dr. Andrew Mulberg

Dr. Andrew Mulberg

Regulatory Advisor

Dr. Andrew Mulberg is a pharmaceutical executive and pediatric gastroenterologist with over 20 years of experience in drug development and regulatory affairs. He served as Division Deputy Director at the FDA’s Division of Gastroenterology and Inborn Errors Products and held senior roles at Amicus Therapeutics and Johnson & Johnson. He earned his B.A. from Columbia University and M.D. from Mount Sinai School of Medicine.

Dr. Hilary Marston

Dr. Hilary Marston

Regulatory Advisor

Dr. Hilary Marston served as Chief Medical Officer of the U.S. Food and Drug Administration (FDA). Her expertise spans regulatory science and public health policy. At FDA, she led clinical policy across the agency, including rare disease incentive programs, pediatric labeling, and modernizing clinical trials. Before that, she was Director for Medical and Biodefense Preparedness at the White House National Security Council and a medical officer at NIAID. She earned her M.D. from the University of Pennsylvania and her MPH from Harvard, and trained in internal medicine at Brigham and Women’s Hospital.

Dr. Kush Dhody

Dr. Kush Dhody

Regulatory Advisor

Dr. Kush Dhody is a clinical and regulatory expert with more than 20 years of global experience guiding pharma and biotech companies through FDA, EMA, and ICH pathways, including IND and NDA submissions. As President of Amarex Clinical Research, an NSF company, he leads GCP-compliant development across multiple therapeutic areas. He holds an M.D. (equivalent) and an M.S. in Clinical Research from Cranfield University, UK.

Careers

Join us

We’re always interested in hearing from talented people who share our mission and are passionate about making a difference. To be considered for future opportunities, send your résumé to info@interludebio.com, and follow us on LinkedIn for open positions.